<DOC>
	<DOCNO>NCT02296424</DOCNO>
	<brief_summary>The purpose study evaluate efficacy observe canakinumab dose reduction subgroup patient extension study CACZ885G2301E1 .</brief_summary>
	<brief_title>ß-SPECIFIC 4 Patients : Study Pediatric EffiCacy Safety wIth FIrst-line Use Canakinumab</brief_title>
	<detailed_description>This two-part open-label study assess 2 different canakinumab taper regimens patient clinical remission ( inactive disease least 24 continuous week ) canakinumab treatment without concomitant corticosteroid ( CS ) methotrexate ( MTX ) . The study also collect long term safety tolerability data SJIA patient treat canakinumab .</detailed_description>
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Juvenile</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Cohort 1 : • Patients receive canakinumab treatment ( 4 mg/kg every 4 week ) Systemic Juvenile Idiopathic Arthritis ( SJIA ) inactive disease last visit Study CACZ885G2301E1 Cohort 2 : Confirmed diagnosis SJIA per International League Against Rheumatism ( ILAR ) definition must occur least 2 month prior enrollment onset disease &lt; 16 year age . Active SJIA define 2 following : Documented spiking , intermittent fever ( body temperature &gt; 38°C ) least 1 day within 1 week first canakinumab dose ; At least 2 joint active arthritis Creactive protein ( CRP ) &gt; 30 mg/L ( normal range &lt; 10 mg/L ) Rash due SJIA Serositis Lymphadenopathy Hepatosplenomegaly Negative TB screen ( QuantiFERON , require local guideline , Purified Protein Derivative ) . With active recurrent bacterial , fungal viral infection time enrollment , include patient evidence Human Immunodeficiency Virus ( HIV ) infection , Hepatitis B Hepatitis C infection . With underlying metabolic , renal , hepatic , infectious gastrointestinal condition opinion investigator immunocompromises patient /or place patient unacceptable risk participation . With neutropenia ( absolute neutrophil count &lt; 1500/mm3 ) screening .</criteria>
	<gender>All</gender>
	<minimum_age>2 Years</minimum_age>
	<maximum_age>20 Years</maximum_age>
	<verification_date>September 2016</verification_date>
</DOC>